[go: up one dir, main page]

WO1998039359B1 - Dimeric cationic lipids on dicystine basis - Google Patents

Dimeric cationic lipids on dicystine basis

Info

Publication number
WO1998039359B1
WO1998039359B1 PCT/US1998/004349 US9804349W WO9839359B1 WO 1998039359 B1 WO1998039359 B1 WO 1998039359B1 US 9804349 W US9804349 W US 9804349W WO 9839359 B1 WO9839359 B1 WO 9839359B1
Authority
WO
WIPO (PCT)
Prior art keywords
cationic lipids
dicystine
basis
dimeric cationic
alk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/004349
Other languages
French (fr)
Other versions
WO1998039359A1 (en
Filing date
Publication date
Priority claimed from US08/812,771 external-priority patent/US6034135A/en
Application filed filed Critical
Priority to CA002281915A priority Critical patent/CA2281915A1/en
Priority to DE69815075T priority patent/DE69815075T2/en
Priority to EP98910189A priority patent/EP0968227B1/en
Priority to AU64488/98A priority patent/AU732333B2/en
Publication of WO1998039359A1 publication Critical patent/WO1998039359A1/en
Publication of WO1998039359B1 publication Critical patent/WO1998039359B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

The present invention provides novel dimeric cationic lipids. The present invention further provides compositions of these lipids with anionic or polyanionic macromolecules, methods for interfering with protein expression in a cell utilizing these compositions and a kit for preparing the same.

Claims

AMENDED CLAIMS[received by the International Bureau on 25 September 1998 (25.09.98); original claim 1 amended; remaining claims unchanged (1 page)]
1. A compound of the formula
Z - S - S - Z wherein Z is
Figure imgf000003_0001
wherein (a) n is 0, 1 or 2; (b) R- is hydroxy, a glyceryl moiety or a lipophilic moiety;
!c) R2 is
(i) -NH- [alk-- H]nl- wherein nl is an integer from 0 to 2 and alk: is an alkylene group of 2 to S carbon atoms;
(ϋ) -[W n2- wherein n2 is an integer from 0 to 3 and each W: is an independently selected amino acid residue;
Figure imgf000003_0002
wherein R4 is hydrogen, alkyl of 1 to 18 carbon atoms optionally mono-, di- or tri-substituted with Y1# Y2 and/or Y3 ;
PCT/US1998/004349 1997-03-06 1998-03-05 Dimeric cationic lipids on dicystine basis Ceased WO1998039359A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002281915A CA2281915A1 (en) 1997-03-06 1998-03-05 Dimeric cationic lipids on dicystine basis
DE69815075T DE69815075T2 (en) 1997-03-06 1998-03-05 DICYSTINE-BASED DIMERATION CATIONIC LIPIDS
EP98910189A EP0968227B1 (en) 1997-03-06 1998-03-05 Dimeric cationic lipids on dicystine basis
AU64488/98A AU732333B2 (en) 1997-03-06 1998-03-05 Dimeric cationic lipids on dicystine basis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/812,771 US6034135A (en) 1997-03-06 1997-03-06 Dimeric cationic lipids
US08/812,771 1997-03-06

Publications (2)

Publication Number Publication Date
WO1998039359A1 WO1998039359A1 (en) 1998-09-11
WO1998039359B1 true WO1998039359B1 (en) 1998-11-26

Family

ID=25210580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004349 Ceased WO1998039359A1 (en) 1997-03-06 1998-03-05 Dimeric cationic lipids on dicystine basis

Country Status (6)

Country Link
US (1) US6034135A (en)
EP (1) EP0968227B1 (en)
AU (1) AU732333B2 (en)
CA (1) CA2281915A1 (en)
DE (1) DE69815075T2 (en)
WO (1) WO1998039359A1 (en)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2365625A1 (en) * 1999-03-10 2000-09-14 Phogen Limited Delivery of substances to cells
KR20010102370A (en) * 1999-03-11 2001-11-15 후지야마 아키라 Liposome preparations
JP2003507430A (en) * 1999-08-25 2003-02-25 ジーエムピー カンパニーズ，インコーポレーテッド Drugs that enhance oxygen transport in mammals
US7102024B1 (en) 2000-08-01 2006-09-05 Schwartz David A Functional biopolymer modification reagents and uses thereof
US6686461B1 (en) 2000-03-22 2004-02-03 Solulink Bioscience, Inc. Triphosphate oligonucleotide modification reagents and uses thereof
AU4769701A (en) 2000-03-22 2001-10-03 Solulink Inc Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
AU2003245160B2 (en) 2002-06-28 2009-09-24 Arbutus Biopharma Corporation Method and apparatus for producing liposomes
EP2239329A1 (en) 2003-03-07 2010-10-13 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
EP2666858A1 (en) 2003-04-17 2013-11-27 Alnylam Pharmaceuticals Inc. Modified iRNA agents
NZ581166A (en) * 2003-09-15 2011-06-30 Protiva Biotherapeutics Inc Polyethyleneglycol-modified lipid compounds and uses thereof
US7158353B2 (en) * 2003-11-06 2007-01-02 Seagate Technology Llc Magnetoresistive sensor having specular sidewall layers
US7799565B2 (en) 2004-06-07 2010-09-21 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering RNA
EP1828219A4 (en) * 2004-11-17 2008-07-23 Protiva Biotherapeutics Inc Sirna silencing of apolipoprotein b
CN101346393B (en) 2005-11-02 2015-07-22 普洛体维生物治疗公司 Modified siRNA molecules and uses thereof
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
AU2008342535B2 (en) * 2007-12-27 2015-02-05 Arbutus Biopharma Corporation Silencing of polo-like kinase expression using interfering RNA
US20110117125A1 (en) * 2008-01-02 2011-05-19 Tekmira Pharmaceuticals Corporation Compositions and methods for the delivery of nucleic acids
EP3604533A1 (en) 2008-04-11 2020-02-05 Arbutus Biopharma Corporation Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
WO2009127060A1 (en) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010042877A1 (en) 2008-10-09 2010-04-15 Tekmira Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010083615A1 (en) 2009-01-26 2010-07-29 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein c-iii expression
CA2753975C (en) 2009-03-02 2017-09-26 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
WO2011011447A1 (en) 2009-07-20 2011-01-27 Protiva Biotherapeutics, Inc. Compositions and methods for silencing ebola virus gene expression
WO2011109427A2 (en) 2010-03-01 2011-09-09 Alnylam Pharmaceuticals, Inc. Improving the biological activity of sirna through modulation of its thermodynamic profile
US8455455B1 (en) 2010-03-31 2013-06-04 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes involved in hemorrhagic fever
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
WO2011133868A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Conformationally restricted dinucleotide monomers and oligonucleotides
WO2011133876A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising acyclic and abasic nucleosides and analogs
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
US8466122B2 (en) 2010-09-17 2013-06-18 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
RU2711799C2 (en) 2011-06-21 2020-01-22 Элнилэм Фармасьютикалз, Инк. Mrna composition for protein similar to angiopoietin 3 (angptl3) and methods for use thereof
IN2014CN03463A (en) 2011-11-18 2015-10-09 Alnylam Pharmaceuticals Inc
NZ808402A (en) 2011-11-18 2025-06-27 Alnylam Pharmaceuticals Inc Modified rnai agents
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9789193B2 (en) 2012-06-15 2017-10-17 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
CA2879683C (en) 2012-08-03 2023-02-14 Alnylam Pharmaceuticals, Inc. Modified rnai agents
CN104854242B (en) 2012-12-05 2018-03-16 阿尔尼拉姆医药品有限公司 PCSK9 iRNA compositions and methods of use thereof
US9428453B2 (en) 2013-01-02 2016-08-30 Rutgers, The State University Of New Jersey Cystine diamide analogs for the prevention of cystine stone formation in cystinuria
EP3312281A3 (en) 2013-03-14 2018-06-27 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
CA2912826A1 (en) 2013-05-22 2014-11-27 Alnylam Pharmaceuticals, Inc. Serpina1 irna compositions and methods of use thereof
EA201592225A1 (en) 2013-05-22 2016-04-29 Элнилэм Фармасьютикалз, Инк. COMPOSITIONS BASED ON iRNA TMPRSS6 AND METHODS OF THEIR APPLICATION
WO2015042564A1 (en) 2013-09-23 2015-03-26 Alnylam Pharmaceuticals, Inc. Methods for treating or preventing transthyretin (ttr) associated diseases
EA201691215A1 (en) 2013-12-12 2016-11-30 Элнилэм Фармасьютикалз, Инк. COMPOSITIONS ON THE BASIS OF IRNA TO THE COMPONENT OF THE COMPLEX AND METHODS OF THEIR APPLICATION
US10119136B2 (en) 2014-01-09 2018-11-06 Alnylam Pharmaceuticals, Inc. RNAi agents modified at the 4′-C position
KR20230152154A (en) 2014-02-11 2023-11-02 알닐람 파마슈티칼스 인코포레이티드 KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20160132496A (en) 2014-04-03 2016-11-18 인빅터스 온콜로지 피비티. 엘티디. Supramolecular combinatorial therapeutics
MX382901B (en) 2014-05-22 2025-03-13 Alnylam Pharmaceuticals Inc ANGIOTENSINOGEN (AGT) ARNI COMPOSITIONS AND METHODS OF USING THE SAME.
IL316808A (en) 2014-08-20 2025-01-01 Alnylam Pharmaceuticals Inc Modified double-stranded rna agents and uses thereof
WO2016040589A1 (en) 2014-09-12 2016-03-17 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
CA2968114A1 (en) 2014-11-17 2016-05-26 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
JP2018510621A (en) 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use thereof
WO2016164746A1 (en) 2015-04-08 2016-10-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CA2984636A1 (en) 2015-05-06 2016-11-10 Alnylam Pharmaceuticals, Inc. Factor xii (hageman factor) (f12), kallikrein b, plasma (fletcher factor) 1 (klkb1), and kininogen 1 (kng1) irna compositions and methods of use thereof
EP4365291A3 (en) 2015-06-12 2024-08-14 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en) 2015-06-18 2016-12-22 Alnylam Pharmaceuticals, Inc. Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
AU2016315584B2 (en) 2015-09-02 2022-07-14 Alnylam Pharmaceuticals, Inc. Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof
EP3350328A1 (en) 2015-09-14 2018-07-25 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
EP3387129A1 (en) 2015-12-10 2018-10-17 Alnylam Pharmaceuticals, Inc. STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20190256845A1 (en) 2016-06-10 2019-08-22 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
TW202313978A (en) 2016-11-23 2023-04-01 美商阿尼拉製藥公司 Serpina1 irna compositions and methods of use thereof
JP7058656B2 (en) 2016-12-16 2022-04-22 アルナイラム ファーマシューティカルズ， インコーポレイテッド Methods for Treating or Preventing TTR-Related Diseases with Transthyretin (TTR) iRNA Compositions
TWI801377B (en) 2017-04-18 2023-05-11 美商阿尼拉製藥公司 Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
EP4295895A3 (en) 2017-05-11 2024-03-27 Tc1 Llc Thermal interconnect for implantable blood pump
EP3704252A1 (en) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
CA3086485A1 (en) 2017-12-21 2019-06-27 Alnylam Pharmaceuticals, Inc. Chirally-enriched double-stranded rna agents
JP2022500003A (en) 2018-09-18 2022-01-04 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) iRNA composition and its usage
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
WO2020117840A2 (en) 2018-12-05 2020-06-11 Empirico Inc. Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions
US20220056455A1 (en) 2018-12-20 2022-02-24 Praxis Precision Medicines, Inc. Compositions and methods for the treatment of kcnt1 related disorders
US11116778B2 (en) 2019-01-15 2021-09-14 Empirico Inc. Prodrugs of ALOX-15 inhibitors and methods of using the same
JP2022532652A (en) 2019-05-17 2022-07-15 アルニラム ファーマスーティカルズ インコーポレイテッド Oral delivery of oligonucleotides
WO2021030522A1 (en) 2019-08-13 2021-02-18 Alnylam Pharmaceuticals, Inc. SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
JP2023500661A (en) 2019-11-01 2023-01-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
EP4061945A1 (en) 2019-11-22 2022-09-28 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
BR112022011417A2 (en) 2019-12-13 2022-08-30 Alnylam Pharmaceuticals Inc COMPOSITIONS OF THE IRNA AGENT OF THE OPEN READING PHASE 72 OF HUMAN CHROMOSOME 9 (C9ORF72) AND METHODS OF USE THEREOF
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
EP4114947A1 (en) 2020-03-05 2023-01-11 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
JP2023519274A (en) 2020-03-26 2023-05-10 アルナイラム ファーマシューティカルズ， インコーポレイテッド CORONAVIRUS iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021206917A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021206922A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
JP2023523993A (en) 2020-04-27 2023-06-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド Apolipoprotein E (ApoE) iRNA agent compositions and methods of use thereof
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150078A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
EP4150090A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231685A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231673A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
US11408000B2 (en) 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
WO2021252557A1 (en) 2020-06-09 2021-12-16 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
CN116113697A (en) 2020-07-10 2023-05-12 国家健康与医学研究院 Methods and compositions for treating epilepsy
WO2022066847A1 (en) 2020-09-24 2022-03-31 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
JP2023544413A (en) 2020-10-05 2023-10-23 アルナイラム ファーマシューティカルズ， インコーポレイテッド G protein-coupled receptor 75 (GPR75) iRNA compositions and methods of use thereof
EP4232581A1 (en) 2020-10-21 2023-08-30 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en) 2020-10-23 2022-04-28 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
AU2021385572A1 (en) 2020-11-25 2023-06-22 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CA3201452A1 (en) 2020-12-01 2022-06-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
JP2024508714A (en) 2021-02-12 2024-02-28 アルナイラム ファーマシューティカルズ， インコーポレイテッド Superoxide dismutase 1 (SOD1) iRNA composition and method for using the same for treating or preventing superoxide dismutase 1- (SOD1-) related neurodegenerative diseases
EP4298220A1 (en) 2021-02-25 2024-01-03 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods of use thereof
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
BR112023019981A2 (en) 2021-03-29 2023-12-12 Alnylam Pharmaceuticals Inc COMPOSITIONS OF HUNTINGTINA IRNA AGENT (HTT) AND METHODS OF USE THEREOF
EP4330396A1 (en) 2021-04-29 2024-03-06 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4341401A1 (en) 2021-05-18 2024-03-27 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
WO2022246023A1 (en) 2021-05-20 2022-11-24 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
AR126000A1 (en) 2021-06-04 2023-08-30 Alnylam Pharmaceuticals Inc ARNI AGENTS OF OPEN READING FRAME 72 OF HUMAN CHROMOSOME 9 (C9ORF72), COMPOSITIONS AND METHODS OF USE THEREOF
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
EP4363574A1 (en) 2021-06-29 2024-05-08 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2023003995A1 (en) 2021-07-23 2023-01-26 Alnylam Pharmaceuticals, Inc. Beta-catenin (ctnnb1) irna compositions and methods of use thereof
EP4419683A1 (en) 2021-10-22 2024-08-28 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
JP2024541974A (en) 2021-10-29 2024-11-13 アルナイラム ファーマシューティカルズ， インコーポレイテッド Huntingtin (HTT) iRNA agent compositions and methods of use thereof
JP2025500409A (en) 2021-12-22 2025-01-09 キャンプ４ セラピューティクス コーポレイション Methods for modulating gene transcription using antisense oligonucleotides targeted to regulatory RNAs - Patents.com
EP4469575A2 (en) 2022-01-24 2024-12-04 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
KR20250031230A (en) 2022-05-25 2025-03-06 아카제라 메디신즈, 인크. Lipid nanoparticles for nucleic acid delivery and methods of using the same
CN119731320A (en) 2022-06-10 2025-03-28 4阵营疗法公司 Methods of modulating expression of granulin precursors using antisense oligonucleotides targeted to regulatory RNAs
TW202424193A (en) 2022-09-15 2024-06-16 美商艾拉倫製藥股份有限公司 17β-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4627084A1 (en) 2022-12-01 2025-10-08 Camp4 Therapeutics Corporation Modulation of syngap1 gene transcription using antisense oligonucleotides targeting regulatory rnas
WO2025015338A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025015335A1 (en) 2023-07-13 2025-01-16 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
WO2025034422A1 (en) 2023-08-04 2025-02-13 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating ctnnb1-associated disorders
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2645866B1 (en) * 1989-04-17 1991-07-05 Centre Nat Rech Scient NEW LIPOPOLYAMINES, THEIR PREPARATION AND THEIR USE
EP0544824B1 (en) * 1990-07-27 1997-06-11 Isis Pharmaceuticals, Inc. Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression
AU9094991A (en) * 1990-11-23 1992-06-25 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
US5777153A (en) * 1994-07-08 1998-07-07 Gilead Sciences, Inc. Cationic lipids
CA2223088A1 (en) * 1995-06-07 1996-12-19 Bob Dale Brown Novel carbamate-based cationic lipids
US6020526A (en) * 1995-07-21 2000-02-01 Genta, Incorporated Amide-based cationic lipids
WO1998013377A1 (en) * 1996-03-06 1998-04-02 Biomolecular Research Institute Ltd. Cytotoxic peptides

Similar Documents

Publication Publication Date Title
WO1998039359B1 (en) Dimeric cationic lipids on dicystine basis
WO1998039358B1 (en) Oligomeric cationic lipids
EP1815859A3 (en) Halimide, a cytotoxic marine natural product, and derivatives thereof
CA2105014A1 (en) Imidazolidine derivatives
RU94040390A (en) Derivatives of vinyleneazaindole, method of their synthesis, pharmaceutical composition
NZ326238A (en) Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
CA2153979A1 (en) Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents
CA2446619A1 (en) Permeation enhancers
CA2180205A1 (en) Triazinyl or pyrimidinyl group-containing amino-silicones
WO1994020463B1 (en) Novel distamycin analogues
CA2053820A1 (en) Method of Inhibiting Metabolism of Cholesterol
CA2446622A1 (en) Isostearic acid salts as permeation enhancers
CA2299429A1 (en) New lipopolyamines,their preparation and the use thereof
KR910016771A (en) Lipopeptide Derivatives
CA2489576A1 (en) Compositions and methods for darkening the skin
AU9479098A (en) Enhanced efficacy stable antiperspirant active solution and method of making same
RU2205186C2 (en) Labeled analogues of glutamine and lysine
TW284765B (en)
CA2211568A1 (en) Organosilicon compounds containing amino groups, their preparation and their use
CA2334821A1 (en) Chemical synthesis of morpholine derivatives
TR199800403A2 (en) I won during the preparation of a-Bromo-lactam tablets.
TR200504091T2 (en) (7alpha, 17alpha) -17-hydroxy-7-methyl-19-nor-17-pregn-5 (10) -en 20-yn-3-one.
AU6132499A (en) Novel mercaptans and disulfides
EP1057825A4 (en) Isoflavane derivatives and immunopotentiating compositions containing the same
CA2217026A1 (en) New antiviral substituted pyrimidinedione homocarbocyclic nucleoside derivatives and methods for the preparation thereof and compositions containing the same as active ingredients